# A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

> **NCT04784897** · PHASE2 · COMPLETED · sponsor: **Innovation Pharmaceuticals, Inc.** · enrollment: 120 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Brilacidin
- **DRUG:** Placebo
- **DRUG:** Standard of Care (SoC)

## Key facts

- **NCT ID:** NCT04784897
- **Lead sponsor:** Innovation Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-22
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04784897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04784897, "A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04784897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*